Physician profile
Timothy Brooks
NPI 1558365189
$1,822.69
in general payments reported to CMS, 2019-2025
28 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $142 · 2021: $343 · 2022: $277 · 2023: $283 · 2024: $76.36 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $205.05 | 2019-2023 | Vaxneuvance, Vaqta, Vaxelis |
| Lilly USA, LLC | $199.06 | 2019-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $158.67 | 2021-2024 | Qulipta |
| Abbott Laboratories | $132.57 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.78 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $90.56 | 2022-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $73.96 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $69.42 | 2019-2023 | |
| Novo Nordisk INC | $65.39 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $64.08 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $57.02 | 2022 | |
| Amgen INC. | $48.53 | 2020-2025 | Evenity, Prolia |
| Verona Pharma, INC. | $48.47 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $42.20 | 2023-2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.29 | 2021-2023 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $39.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.29 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.85 | 2019-2020 | |
| Exact Sciences Corporation | $31.67 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $29.93 | 2021-2025 | Trelegy Ellipta |
| Allergan, INC. | $25.12 | 2019-2020 | |
| Alkermes, INC. | $23.34 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.71 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $18.53 | 2021 | |
| Sanofi Pasteur INC. | $16.97 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.26 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.